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Summary
In 40% of cases of classical Hodgkin lymphoma (cHL), Epstein–Barr virus
(EBV) latency-II antigens [EBV nuclear antigen 1 (EBNA1)/latent
membrane protein (LMP)1/LMP2A] are present (EBV1cHL) in the
malignant cells and antigen presentation is intact. Previous studies have
shown consistently that HLA-A*02 is protective in EBV1cHL, yet its role in
disease pathogenesis is unknown. To explore the basis for this observation,
gene expression was assessed in 33 cHL nodes. Interestingly, CD8 and
LMP2A expression were correlated strongly and, for a given LMP2A level,
CD8 was elevated markedly in HLA-A*02– versus HLA-A*021 EBV1cHL
patients, suggesting that LMP2A-specific CD81 T cell anti-tumoral
immunity may be relatively ineffective in HLA-A*02– EBV1cHL. To
ascertain the impact of HLA class I on EBV latency antigen-specific
immunodominance, we used a stepwise functional T cell approach. In newly
diagnosed EBV1cHL, the magnitude of ex-vivo LMP1/2A-specific CD81 T
cell responses was elevated in HLA-A*021 patients. Furthermore, in a
controlled in-vitro assay, LMP2A-specific CD81 T cells from healthy HLA-
A*02 heterozygotes expanded to a greater extent with HLA-A*02-restricted
compared to non-HLA-A*02-restricted cell lines. In an extensive analysis of
HLA class I-restricted immunity, immunodominant EBNA3A/3B/3C-
specific CD81 T cell responses were stimulated by numerous HLA class I
molecules, whereas the subdominant LMP1/2A-specific responses were
confined largely to HLA-A*02. Our results demonstrate that HLA-A*02
mediates a modest, but none the less stronger, EBV-specific CD81 T cell
response than non-HLA-A*02 alleles, an effect confined to EBV latency-II
antigens. Thus, the protective effect of HLA-A*02 against EBV1cHL is not a
surrogate association, but reflects the impact of HLA class I on EBV latency-
II antigen-specific CD81 T cell hierarchies.
Keywords: classical Hodgkin lymphoma, Epstein–Barr virus, genetic associ-
ations, HLA class I, T cell immunity
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Introduction
Epstein–Barr virus (EBV) is a ubiquitous, persistent B cell-
trophic virus that typically establishes a benign infection of
minimal clinical consequence. However, in a minority of
hosts, EBV is associated with particular malignancies. In
these conditions, EBV resides within the malignant cell in a
restricted state of latent antigen expression. The frequency
of association and expression of latent proteins is distinc-
tive to the type of cancer. In classical Hodgkin lymphoma
(cHL), approximately 40% of cases are associated with
EBV (EBV1cHL), and virus expression in the Hodgkin–
Reed–Sternberg (HRS) cells is limited to the EBV nuclear
antigen 1 (EBNA1) and latent membrane proteins (LMP1
and LMP2)[1–3]. These are collectively termed EBV
latency-II antigens, a pattern of expression also observed in
undifferentiated nasopharyngeal carcinoma. EBV1cHL is
characterized by intact human leucocyte antigen (HLA)
class I antigen processing and presentation [4–7], enabling
successful treatment of relapsed EBV1cHL by adoptive
immunotherapy targeting EBV latency-II antigens [8–11].
A well-established hierarchy exists among CD81 T cell
responses that target EBV latency antigens. In particular,
EBV latency-III antigens EBNA3A/3B/3C are immuno-
dominant, whereas the EBV latency-II antigens (EBNA1/
LMP1/LMP2A) are subdominant and more challenging to
detect without in-vitro expansion [12,13]. However, the
impact of HLA class I on EBV latency antigen-specific
CD81 T cell immunity has not been determined system-
atically. Interestingly, large epidemiological and genome-
wide association studies have consistently reported
differential HLA class I susceptibility to EBV1cHL
(Supporting information, Table S1) [14–17]. In western
European populations, HLA-A*01 and HLA-B*37 are
associated with increased susceptibility to EBV1cHL,
while HLA-A*02 is associated with protection [15–17]. By
contrast, the HLA-A*02 subtype HLA-A*0207, which
presents HLA-A*0201-restricted LMP2A-derived peptides
poorly [18], is over-represented in northern Chinese
EBV1cHL patients [19]. Non-HLA-linked genetic suscep-
tibility loci have also been identified for cHL, as has a sin-
gle nucleotide polymorphism (SNP) found in association
with an HLA class II locus. However, these associations
were not specific for EBV1cHL [14,20,21].
The aim of this study was to understand the role of HLA
class I in the pathogenesis of EBV1cHL. The presentation
of viral peptide determinants by HLA-A*02 and non-HLA-
A*02 molecules provides a potential mechanistic link
between EBV latency-II-specific CD81 T cell immunity
and the described genetic associations with EBV1cHL.
However, there are many genes with diverse functions in
close proximity to HLA class I. Therefore, such associations
may simply reflect linkage disequilibrium between HLA
class I and the ‘true’ predisposition locus. To distinguish
these possibilities, we analysed the impact of HLA-A*02
and non-HLA-A*02 molecules on EBV latency-II antigen-
specific effector CD81 T cell immunity in EBV1cHL.
Materials and methods
Sample cohorts
Blood samples and diseased tissue from newly diagnosed
cHL patients and blood samples from healthy participants
were acquired as part of an Australasian Leukaemia and
Lymphoma Group prospective observational study. EBV
association was confirmed via EBV-encoded-RNA in-situ
hybridization (EBER-ISH), as described previously [22].
Peripheral blood mononuclear cells (PBMCs) were isolated
and cryopreserved in 90% fetal bovine serum (FBS) with
10% dimethylsulphoxide (DMSO). This study conformed
to the Declaration of Helsinki and was approved by the
Human Research Ethics Committees at all participating
institutions. Written informed consent was obtained in all
cases.
Digital multiplex gene expression by NanoString
nCounter
Nucleic acid was extracted from 33 cHL formalin-fixed
paraffin-embedded (FFPE) diseased node tissues (17
EBV-vecHL, 16 EBV1cHL) using a RecoverAll Total
Nucleic Acid Extraction Kit (Life Technologies, Paisley,
UK). Gene expression profiling was conducted using
the nCounter platform (NanoString Technologies). All
analyses were performed using NCounter software. For
normalization, gene expression data were controlled inter-
nally to the mean of the positive control probes to
account for interassay variability. Gene normalization
was performed using the geometric mean of four house-
keeper genes [phosphoglycerate kinase 1 (PGK1),
glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
phosphoglycerate mutase 1 (PGAM1), ornithine decar-
boxylase anti-zyme 1(OAZ1)], selected as per the manu-
facturer’s recommendation.
Ex-vivo EBV-specific CD81 T cell responses
Peptide pools (17-mers overlapping by 10 amino acids)
were synthesized to span the entire lengths of LMP1,
LMP2A and BamHI Z fragment leftward open reading
frame 1 (BZLF1) (Synbiosci, San Francisco, CA, USA and
Mimotopes, Notting Hill, VIC, Australia). Each individual
peptide in each pool was used at a final concentration of
2 lg/ml to stimulate EBV-specific CD81 T cells. Initially,
PBMCs from 19 pretreatment EBV-seropositive cHL
patients (eight EBV1cHL, 11 EBV–cHL) were assayed. Sub-
sequently, PBMCs from 14 EBV-seropositive healthy volun-
teers were analysed at a separate site. PBMCs were
resuspended in culture medium containing the co-
stimulatory antibodies aCD28 and aCD49d (1 lg/ml each;
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BD Pharmingen, Franklin Lakes, NJ, USA), brefeldin A
(Golgi Plug, 10 lg/ml; BD Biosciences), monensin (Golgi
Stop, 0.7 lg/ml; BD Biosciences) and fluorochrome-
labelled aCD107a. Each sample was divided into five stim-
ulations: LMP1, LMP2A, BZLF1, an unstimulated control
(co-stimulation only) and a positive control comprising
either Staphyloccoccus enterotoxin B (01 lg/ml; Sigma-
Aldrich, St Louis, MO, USA) or phorbol myristate acetate
(10 ng/ll) with ionomycin (2 lg/ml). Cells were cultured
overnight at 1–2 3 106 cells/ml in a 378C, 5% CO2 incuba-
tor. The following day, PBMCs were washed, labelled with
a viability dye to enable dead cell exclusion and surface-
stained for CD3, CD4 and CD8. Cells were then fixed/
permeabilized and stained intracellularly for interferon
(IFN)-g and tumour necrosis factor (TNF)-a. All staining
procedures were conducted as described previously [23].
Samples were acquired on an LSRII flow cytometer (BD
Biosciences) and data analysis was performed using FlowJo
version 92 (TreeStar Inc., Ashland, OR, USA). The gating
strategy followed previously published standard practice
and is shown in Supporting information, Fig. S1 [24].
LMP2A-specific CD81 T cell expansion using
monogenic HLA class I cell lines
Nine healthy EBV-seropositive HLA-A*02 heterozygotes
(three HLA-A*01/A*02, three HLA-A*02/A*03 and three
HLA-A*01/A*02/B*08) were tested. PBMCs were stimu-
lated with HLA class I-deficient, EBV-infected 721221
lymphoblastoid cell lines transfected separately with HLA-
A*01, A*02, A*03 or B*08. Procedures were adapted from a
previously published protocol [25]. Each transfected
721221 cell line was pulsed with overlapping LMP2A
peptide pools spanning the entire protein (Synbiosci). Pep-
tides were divided into six pools (Supporting information,
Table S2), each comprising 10–11 peptides at a final indi-
vidual concentration of 10 lg/ml. These smaller pools at
higher concentrations were used to maximize the antigen-
specific stimulus (a single pool of all 65 peptides at this
high concentration would have been toxic). The corre-
sponding unpulsed cells served as baseline controls in all
experiments. Cultures were expanded for 10 days under
standard conditions. The relative strength of the HLA class
I-restricted EBV-specific CD81 T cell response was assessed
using intracellular cytokine staining for IFN-g after a 5-h
restimulation. Samples were acquired on a fluorescence
activated cell sorter (FACS)Canto flow cytometer (BD Bio-
sciences) and data analysis was performed using FlowJo
version 92 (TreeStar Inc.).
In-vitro LMP2A-specific CD81 T cell cytotoxicity
EBV-specific T cells were expanded by repeated stimulation
with autologous EBV-transformed B cells for 6–8 weeks
using a published expansion protocol [26,27] in four EBV-
seropositive healthy control donors (two HLA-A*021 and
two HLA-A*02–). Direct lysis of autologous EBV-
transformed B cells was confirmed in all cases, demonstrat-
ing successful expansion of cytotoxic EBV-specific T cells.
LMP2A-specific cytotoxicity was quantified using autolo-
gous carboxyfluorescein succinimidyl ester (CFSE)-labelled
phytohaemagglutinin (PHA) blasts (target cells) incubated
with 2 lg/ml of peptides from each of six LMP2A overlap-
ping peptide pools (Supporting information, Table S2) in
duplicate. The ratio of effector to target cells was 20 : 1.
After 6 h incubation, the number of CFSE-labelled targets
remaining was determined by comparison to a constant
number of CountBright absolute counting beads (Thermo-
Fisher, Scoresby, Australia). LMP2A-specific lysis was cal-
culated for each well relative to the unpulsed control
sample.
HLA class I-restricted EBV latency antigen-specific
CD81 T cell responses
Ex-vivo CD107ab1CD81 T cell responses to HLA class
I-restricted peptides were assayed in 30 healthy EBV-
seropositive donors. PBMCs were resuspended in culture
medium containing monensin (GolgiStop, 0.7 lg/ml; BD
Biosciences), aCD107a-fluorescein isothiocyanate (FITC)
and aCD107b-FITC (BD Pharmingen), and incubated for
5 h with peptide (2 lg/ml). Samples were acquired on a
FACSCanto flow cytometer (BD Biosciences) and data
analysis was performed using FlowJo version 92 (TreeStar
Inc.). To minimize bias, an equivalent number of ‘pre-
dicted’ and ‘defined’ (31 and 30, respectively) peptides
were included. The peptides were derived from LMP1/
LMP2A or EBNA3A/3B/3C and restricted by one of the fol-
lowing HLA class I allotypes: HLA-A*01, A*02, A*03,
A*11, A*24, B*07, B*08, B*35, B*37, B*44 or B*60
(B*40:01). Equivalent numbers of defined epitopes cover-
ing comparable numbers of HLA class I alleles were used
for the immunodominant EBNA3A/3B/3C (15 peptides,
six alleles) and the subdominant LMP1/LMP2A (15 pep-
tides, seven alleles) proteins. Combined, these alleles cover
75% of HLA-A and 57% of HLA-B alleles in the Australian
population [28]. Peptides (and references) are listed in
Supporting information, Table S3. All defined epitopes
were validated previously in functional assays. For HLA
class I alleles with few or no known epitopes, predicted
peptides were identified in silico (http://www.syfpeithi.de)
using a previously described algorithm [29]. The ‘SYFPEI-
THI’ scores of defined epitopes were used to delineate a
threshold score for the predicted peptides.
HLA class I peptide binding of algorithm-predicted
peptides
Binding of predicted HLA-A*03-restricted peptides was
confirmed using HLA-A*03-expressing T2 cell lines, as
described previously [30]. Expression of stabilized HLA-
A*03 on the cell surface after peptide pulsing was assessed
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by flow cytometry. Results are reported as the mean fluo-
rescence intensity above the negative (no peptide) control.
Binding of predicted HLA-A*01-restricted peptides was
confirmed by in-vitro HLA-A*0101-peptide complex refold-
ing and thermal stability analysis by circular dichroism
(CD) spectroscopy. Competent Rosetta DE3 Escherichia coli
cells were used to produce the HLA-A*0101 and beta 2-
microglobulin (b2M) chains, as described previously [31].
For a 1-l refold, 30 mg of HLA-A*0101 was mixed with
30 mg of b2M and 4 mg of peptide at 378C for 15 min. The
mixture was then added to cold refold buffer [50 mM Tris
pH 8, 2 mM ethylenediamine tetraacetic acid (EDTA),
400 mM L-arginine, 6 mM cysteamine hydrochloride and
4 mM cystamine]. Refolds were stirred at 48C for> 1 h.
Dialysis was carried out against 10 mM Tris pH 8.1 until
the conductivity of the refolds was <2mS/cm. The refolds
were then filtered, purified by ion exchange using a
Poros50HQTM column and gel filtered into phosphate-
buffered saline (PBS) using a Superdex200HRTM column.
Protein quality was analysed by Coomassie-stained sodium
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE). After ion exchange, the central five fractions around
the maximum HLA class I peak (by SDS gel) from each
refold were selected for gel filtration. After gel filtration, the
central four fractions around the maximum HLA class I
peak from each refold were selected for analysis by spec-
trometry (A280 nm) to determine the final protein yield.
Two positive control peptides from cytomegalovirus,
VTEHDTLLY [32] and YSEHPTFTSQY [25], and a negative
control peptide with a binding sequence optimal for HLA-
A*0201 (ALAAAAAAV), were used in addition to the 13
predicted HLA-A*01-restricted EBV-derived peptides.
Thermal stability of HLA-A*0101/b2M/peptide com-
plexes was assessed by CD spectroscopy. Data were collected
on an Aviv Model 215 spectropolarimeter (Aviv Biomedical
Inc., Lakewood, NJ, USA) equipped with a Peltier thermo-
statted cell holder using a 01-cm quartz cell. Proteins were
dissolved in 75 mM NaCl, 20 mM PO–4, pH 75. Melting
curves were recorded in 058C intervals from 48C up to a
maximum temperature when protein aggregation was
observed with settings resulting in an average heating rate
of 308C/h. Values were corrected to a calibration curve
recorded with the temperature measured in the cell. Melting
curves were analysed assuming a two-state trimer-to-mono-
mer transition from the native (N) to unfolded (U) confor-
mation N3 $ 3U with an equilibrium constant K5 [U]3/
[N3]5 F/[3c
2 (1-F)3], where F and c are the degree of fold-
ing and protein concentration, respectively. Data were fitted
as described [33] using the non-linear least-squares routine
of Origin version 75 (OriginLab, Northampton, MA,
USA). Fitted parameters were the melting temperature TM,
at which 50% of proteins are in the folded and unfolded
state, van’t Hoff ’s enthalpy DHvH at the transition midpoint
and the slope and H-intercept of the native baseline
assumed as a linear function of the temperature. As all pro-
tein complexes aggregated at various degrees of unfolding,
the ellipticity of the unfolded state was set as a constant of
24400 degrees cm2 dmol21; this value resulted from fitting
melting curves of LMP2ALTE and positive control peptide
VTEHDTLLY-containing complexes, which showed the
least aggregation tendency, and is in good agreement with
values reported for other thermally denatured proteins [34].
For all peptides, the coefficient of determination for fitted
curves versusmeasurements was r2> 099.
Statistical analysis
Combined (but not summed) IFN-g, TNF-a and CD107a
responses to EBNA1/LMP1/LMP2A/BZLF1 in patients with
cHL and healthy volunteers were compared using a linear
mixed-effects model (with a random effect for subject). This
enabled comparison of groups while accounting for the cor-
relation induced by measuring multiple (but not necessarily
comparable) responses in the same individual [35]. Using
SPICE (software version 53, downloaded from http://exon.
niaid.nih.gov), individual and polyfunctional IFN-g, TNF-a
and CD107a responses in patients with cHL were compared
by Wilcoxon’s signed-rank tests and a partial permutation
test, as described previously [36]. Healthy donor ex-vivo
CD107ab1CD81 T cell responses against defined and pre-
dicted HLA class I-restricted peptides from LMP1/LMP2A
and EBNA3A/3B/3C were compared using the Mann–Whit-
ney U-test. In cases where responses against multiple peptides
were measured in the same individual, individual responses
were considered independent. Significance above zero was
determined using a one-sample t-test with one-tailed P-val-
ues. Cytotoxicity was compared using Fisher’s exact test with
a two-tailed P-value. Statistical analysis was performed using
GraphPad Prism version 50 (Graphpad Software Inc., San
Diego, CA, USA) and SPSS statistics version 19 (IBM,
Armonk, NY, USA).
Results
Intratumoral CD8 : LMP2A ratios are enriched in
HLA-A*02– EBV1cHL
Gene expression was quantified in 33 cHL diseased node
FFPE tissues (17 EBV–cHL, 16 EBV1cHL) using Nano-
String nCounter [37]. The expression levels of CD8 and
b2M as markers of immune effector and antigen presenta-
tion, respectively, and the EBV latency II genes (EBNA1,
LMP1 and LMP2A with the EBV-lytic gene BZLF1 as a
comparator) were measured. CD8 expression correlated
with b2M in the entire cHL cohort (r5 05906,
P5 00003), consistent with intratumoral CD8 being pro-
portional to antigen presentation. In the EBV1cHL sub-
group, the b2M–CD8 correlation was more marked
(r5 07176, P5 00024, Fig. 1a). In this subgroup, b2M
also correlated with LMP2A levels (r5 05685, P5 00216,
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Fig. 1b). Accordingly, CD8 expression correlated with
LMP2A (r5 07938, P5 00004, Fig. 1c). No correlations
were found for the other EBV genes with either CD8 or
b2M, and there was no difference in expression of CD8 or
b2M between EBV1 and EBV–cHL.
Both EBNA1 and LMP1 are known to encode for anti-
genic peptides that expand IL-10-secreting regulatory
CD41 T cells [38,39]. However, no correlations were found
between the EBV latency II genes and expression of either
CD4 or the regulatory T cell markers IL-10, lymphocyte-
activation gene 3 (LAG3) and forkead box protein 3
(FoxP3) [P5not significant (n.s.)].
Comparisons of HLA-A*021 (n 5 5) and HLA-A*02– (n
5 11) patients with EBV1cHL showed no difference in
expression levels of b2M, CD8, LMP2A or any of the other
EBV genes. However, CD8 and b2M (normalized to the
expression of LMP2A) were elevated markedly in HLA-
A*02– versus HLA-A*021 patients (P5 00087, P5 00087
Fig. 1d,e). This was not observed when expression was nor-
malized to the other EBV latency II genes. These results
demonstrate that, for a given LMP2A expression level,
there is more CD8 and b2M expression within the malig-
nant lymph node in HLA-A*02– compared to HLA-A*021
patients with EBV1cHL.
HLA-A*021 patients with EBV1cHL exhibit increased
responses to EBV latency-II antigens relative to HLA-
A*02– patients
The observation that CD8 is relatively enriched within
HLA-A*02– EBV1cHL nodes suggests that EBV latency-II-
specific effector CD81 T cell immunity is relatively ineffec-
tive in these patients. To investigate the impact of HLA-
A*02 on EBV latency-II-specific effector CD81 T cell
immunity, a series of functional assays were performed.
Initially, we tested CD81 T cell immunity against relevant
EBV latency antigens in pretherapy cHL patients, with EBV
tissue status and HLA class I as covariates. Previous studies
in cHL have not evaluated the contribution of non-defined
subdominant epitopes to the total CD81 T cell response or
assessed whether HLA class I alleles impact the magnitude
of the response [40,41]. Effector molecule testing in these
studies was also limited to IFN-g production.
First, we tested 19 cHL patients (Table 1). Blood samples
were collected at diagnosis prior to therapy. Age and gender
were not significantly different between subgroups, which
were also comparable for Ann Arbor stage and prognostic
score [42]. To ensure that multi-faceted CD81 effector T
cell immunity was assayed, we used polychromatic flow
cytometry to measure ex-vivo IFN-g and TNF-a produc-
tion together with CD107a mobilization. Overlapping pep-
tide pools spanning EBNA1 and the latent proteins LMP1
and LMP2A were used to ensure comprehensive antigenic
coverage. A peptide pool spanning the EBV lytic protein
BZLF1 (not expressed by EBV1 HRS cells) was included as
a comparator. Peptide stimulations were conducted over-
night to enhance sensitivity, and highly stringent gating
strategies were employed to maximize specificity (Support-
ing information, Fig. S1). A linear mixed-effects model was
used to incorporate and compare all three effector markers
and any compounding significance while accounting for
(a) (b) (c)
(e)(d)
Fig. 1. Gene expression in
Epstein–Barr virus (EBV)1
classical Hodgkin lymphoma
(cHL) diseased tissue. (a)
Correlation of beta 2-
microglobulin (b2M) and CD8
expression levels. (b)
Correlation of latent membrane
protein (LMP)2A and b2M
expression levels. (c)
Correlation of LMP2A and CD8
expression levels. Spearman’s
correlation5 r. (d) CD8
expression relative to LMP2A in
human leucocyte antigen
(HLA)-A*021 compared to
HLA-A*02– patients. (e) b2M
expression relative to LMP2A in
HLA-A*021 compared to HLA-
A*02– patients. Error bar
represents standard error of the
mean. Solid black circles
represent HLA-A*021 patients.
Grey circles represent HLA-
A*02– patients.
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multiple measurements within a given individual (repre-
sented in Fig. 2a as summed percentages of IFN-g, TNF-a
and CD107a responses). SPICE software, designed specifi-
cally for post-cytometric complex multivariate data sets,
was used to conduct Wilcoxon signed-rank tests and per-
mutation comparisons on individual (Fig. 2b,c) and poly-
functional (Fig. 2d,e) responses.
Global effector CD81 T cell responses (defined as com-
bined IFN-g, TNF-a and CD107a) were compared for the
EBV latency II proteins (EBNA1, LMP1, LMP2A).
Responses were analysed as total EBV latency II (summed
EBNA1, LMP1/2A-specific), LMP1/2A (summed LMP1/
2A-specific) and individual protein responses. No signifi-
cant differences were found between patients with
EBV1cHL and EBV–cHL. Furthermore, response magni-
tudes across all patients with cHL independent of EBV tis-
sue status were equivalent irrespective of HLA-A*02
expression (Fig. 2a). In addition, the relevant EBV-specific
CD81 T cell responses in patients with EBV–cHL were not
influenced by HLA-A*02 status.
Interestingly, the combined IFN-g, TNF-a and CD107a
CD81 T cell responses were significantly greater in HLA-
A*021 compared to HLA-A*02-ve patients with EBV1cHL
for the LMP1/2A proteins (P5 00371, Fig. 2a). Although
elevated response levels were seen in HLA-A*021
EBV1cHL patients for total EBV latency II (P5 00753)
and individual EBNA1, LMP1 and LMP2A proteins
(P5 03329, P5 00525 and P5 00983, respectively),
these did not reach significance.
We then compared individual immune effector mole-
cules stratified by HLA-A*02 status using SPICE. Although
all three functional markers were elevated in HLA-A*021
compared to HLA-A*02– patients with EBV1cHL for
LMP1/2A proteins (CD107a, 43-fold; IFN-g, 30-fold;
TNF-a, 14-fold), only CD107a reached significance
(P5 0007, Fig. 2b). Across all LMP1/2A-specific effector
CD81 T cells, the proportion of individual effector mole-
cules was significantly different between HLA-A*021 and
HLA-A*02– patients (P5 00041, Fig. 2c). By polyfunc-
tional analysis, this significant increase was attributable to
CD107a single-positive CD81 T cells (CD107a1IFN-
g-TNF-a-; P5 0007, Fig. 2d) and the proportion of poly-
functional immune effectors within all LMP1/2A-specific
CD81 T cells was also significantly different (P5 0043,
Fig. 2e). In HLA-A*021 EBV1cHL patients, the majority of
immune effector cells were CD107a single-positive CD81 T
cells. No differences (P5n.s.) were observed for BZLF1-
specific CD81 T cell responses between any patient
categories.
In line with our findings that differences between HLA-
A*021 and HLA-A*02– patients were detectable only in
EBV1cHL, analysis of 14 healthy age-/sex-matched con-
trols (using the linear mixed-effects model to evaluate com-
prehensive CD81 T cell responses to the EBV latency-II
proteins) revealed no significant differences between HLA-
A*021 (n 5 7) and HLA-A*02– (n 5 7) individuals (Sup-
porting information, Fig. S2a). In patients with cHL, global
effector CD81 T cell responses were greater for LMP2A
compared with LMP1 (P5 0016) and EBNA1
(P< 00001) (Supporting information, Fig. S2b). Similarly,
for healthy controls global effector CD81 T cell responses
were greater for LMP2A compared with LMP1 (P5 0011)
Table 1. Characteristics of classical Hodgkin lymphoma (cHL) patients tested ex vivo for CD81 T cell responses
Patient no. EBER-ISH Age Gender ‘B’ symptoms Stage Prognostic score* Classical subtype HLA-A*02 HLA class I
1 Negative 79 F Yes III 3 NS Negative A*01/*30, B*51/*62
2 Negative 25 M Yes IIIb 3 NS Negative A*11/*11, B*60/*60
3 Negative 79 F No III 1 NS Negative A*01/*31, B*57/*61
4 Negative 33 F Yes IIb 2 LD Negative A*02/*25, B*62/*63
5 Negative 55 M No II 3 MC Positive A*02/*03, B*13/*51
6 Negative 54 M Yes IVb 5 NS Positive A*02/*31, B*44/*60
7 Negative 22 M Yes IVb 5 Classical unspecified Positive A*01/*02, B*35/*57
8 Negative 21 M No IV 3 NS Positive A*02/*03, B*07/*51
9 Negative 27 M No III 3 NS Positive A*02/*03, B*07/*51
10 Negative 20 F No IVa 1 Classical unspecified Positive A*02/*02, B*07/*35
11 Negative 20 F Yes IIIb 3 NS Positive A*01/*02, B*08/*49
12 Negative 18 M No III 2 NS Negative A*11/*24, B*18/*60
13 Positive 48 M No II 2 LR Negative A*24/*24, B*18/*51
14 Positive 40 M No II 1 MC Negative A*01/*24, B*08/*51
15 Positive 40 M Yes IVb 5 NS Negative A*01/*03, B*35/*75
16 Positive 33 M Yes II 2 NS Positive A*02/*29, B*07/B*44
17 Positive 25 F No IIa 0 NS Positive A*02/*02, B*44/*44
18 Positive 49 M No IV 4 NS Positive A*01/*02, B*37/*57
19 Positive 21 F No IIa 1 NS Positive A*02/*66, B*41/*44
*Hasenclever [42]. LD5 lymphocyte-depleted; MC5mixed-cellularity; NS5nodular sclerosing; LR5 lymphocyte-rich; M5male; F5 female;
HLA5 human leucocyte antigen; EBER-ISH5Epstein–Barr virus-encoded-RNA in-situ hybridization.
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and EBNA1, although the latter did not reach statistical sig-
nificance (Supporting information, Fig. S2c).
Thus, by ex-vivo analysis, we observed modest differences
in CD81 T cell responses against relevant EBV latency-II
proteins between HLA-A*021 and to HLA-A*02– patients
with EBV1cHL. These results were not observed in
EBV–cHL patients or healthy participants. In line with our
tissue expression data, these results suggest that EBV
latency-II-specific effector CD81 T cell immunity may be
less effective in HLA-A*02– EBV1cHL.
LMP2A-specific responses restricted by HLA-A*02
achieve greater magnitudes than those restricted by
other HLA class I molecules
Ex-vivo assays are less sensitive than in-vitro expansion for
the detection of low-frequency EBV-specific CD81 T cells
[43]. Indeed, low-frequency responses can be detected
via in-vitro expansion in patients receiving immunosup-
pressive therapies [13]. Furthermore, up to four different
HLA-A/B molecules can potentially present relevant EBV-
derived epitopes in each individual, adding a confounding
layer of complexity to single allele-based effects.
To overcome these limitations, we generated mutant
HLA class I-negative 721221 cell lines transfected individu-
ally with HLA-A*01, HLA-A*02, HLA-A*03 and
HLA-B*08. Previous work with these cell lines demon-
strated an absence of HLA-A*01-restricted responses to
endogenously processed EBV latency antigens. However,
this system was biased preferentially towards the immuno-
dominant EBNA3A/3B/3C antigens that are not expressed
by HRS cells [25]. In order to use this single allele system
to evaluate responses relevant to the EBV1cHL setting,
transfected 721221 cells were pulsed with LMP2A peptides.
LMP2A was chosen for this purpose, as it is the most
immunogenic of the three EBV genes expressed in
EBV1cHL and because it was the only gene we found to
associate significantly with HLA-A*02 in diagnostic tissues.
Overlapping peptides divided into six pools spanning the
entire LMP2A protein were used to ensure inclusion of the
total CD81 T cell response restricted by each HLA class I
molecule, regardless of the specific target epitopes (Sup-
porting information, Table S2). PBMCs from healthy EBV-
seropositive participants were stimulated separately with
each peptide pool to expand LMP2A-specific CD81 T cells.
The results were summed for each allele. Nine EBV-
seropositive donors were tested, all heterozygous for HLA-
(a)
(b)
(c) (e)
(d)
Fig. 2. Ex-vivo Epstein–Barr virus
(EBV)-specific CD81 T-cell
responses in patients with classical
Hodgkin lymphoma (cHL) . (a)
Summed percentages of ex-vivo
latent membrane protein (LMP)1/
2A-specific CD81 T cell responses
defined by interferon (IFN)-g,
tumour necrosis factor (TNF)-a and
CD107a. Error bars represent
standard error of the mean. P-values
were calculated using a linear mixed
effects model. (b–c) Comparison of
individual effector molecules in
human leucocyte antigen (HLA)-
A*021 versus HLA-A*02-ve patients
with EBV1cHL. (b) Percentage of
total CD81 T cells specific for
LMP1/2A. (c) Percentage of the
total LMP1/2A-specific CD81 T cell
subset. (d–e) Comparison of
polyfunctional LMP1/2A-specific
CD81 T cell responses in HLA-
A*021 versus HLA-A*02-ve patients
with EBV1cHL. (d) Percentage of
total CD81 T cells specific for
LMP1/2A. (e) Percentage of the
total LMP1/2A-specific CD81 T cell
subset. **P< 001; *P< 005;
P> 0055 not significant.
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A*02. Other HLA class I donor alleles were selected based
on the literature. Notably, HLA-A*01 has been associated
consistently with an increased incidence of EBV1cHL
[15–17]. HLA-B*08 is known to be in linkage disequili-
brium with HLA-A*01 [44], and a functionally defined
HLA-B*08-restricted LMP2A-derived epitope was identi-
fied recently [45]. Finally, HLA-A*03 was chosen as a rela-
tively common HLA class I allele in Australia. Together,
these four alleles represent> 75% of the Australian popula-
tion [46]. Accordingly, donors 1–3 were HLA-A*01/A*02,
donors 4–6 were HLA-A*02/A*03 and donors 7–9 were
HLA-A*01/A*02/B*08.
IFN-g-specific CD81 T cells inhibit in-vitro transforma-
tion of EBV-infected B cells [47,48]. The cytokine may also
play a critical role in the pathogenesis of cHL via the
canonical Janus kinase–signal transducer and activator of
transcription (JAK–STAT) pathway known to be over-
expressed in HRS cells [49]. Therefore, identifying any dif-
ferences in IFN-g-specific CD81 T cell responses has
important implications. In-vitro expansion permitted more
sensitive discrimination of the impact of HLA class I status
on IFN-g1 responses. As shown in Fig. 3, HLA-A*02 uni-
formly expanded more LMP2A-specific IFN-g1 CD81 T
cells. The total response for each HLA class I allele (i.e. all
HLA-A*01, all HLA-A*02, all HLA-A*03 and all HLA-
B*08) was significantly greater than zero only for HLA-
A*02 (P5 00034). Thus, in an in-vitro system with few
confounding influences, HLA-A*02 generated more
LMP2A-specific IFN-g1 CD81 T cells compared to HLA-
A*01, HLA-A*03 and HLA-B*08.
Of note, peptide pool 5 generated the greatest response
(37% of the total HLA-A*02-restricted responses) and con-
tained the sequences of two known HLA-A*02 epitopes
(FLYALALLL, LLWTLVVL) [12]. Peptide pool 6 contained
the sequences of three known HLA-A*02 epitopes
(CLGGLLTMV, LTAGFLIFL and LLSAWILTA) and gener-
ated 22% of the total HLA-A*02-restricted responses. Pep-
tide pool 4 also generated 22% and contained the sequence
of an identified HLA-A*02 epitope (GLGTLGAAL). Pools
1–3 did not contain known HLA-A*02 epitopes and gener-
ated 4, 8 and 7% of the total HLA-A*02-restricted
responses, respectively.
To confirm that functional LMP2A-specific responses
restricted by HLA-A*02 achieve greater magnitudes than
those restricted by other HLA class I molecules in conven-
tional cytotoxicity assays, we took advantage of a published
expansion protocol that generates EBV-specific CD81 T
cells for therapeutic use [26,27]. This method uses autolo-
gous EBV-transformed B cells as antigen-presenting cells,
thus not only is it physiologically relevant but it expands a
broad range of EBV latent antigen-specific CD81 T cells
across multiple HLA class I alleles. The latter is an impor-
tant point, because it permits a comparison of HLA-A*02
versus non-HLA-A*02 LMP2A-specific CD81 T cells in a
setting in which other EBV latent antigens, including those
presented by other HLA class I alleles, are also presented.
Consistent with earlier results, minimal killing was observed
in non-HLA-A*02 participants (<5% mean LMP2A-
specific killing), whereas strong killing was observed in
HLA-A*02 individuals (>54% mean LMP2A-specific kill-
ing; P< 00001; Supporting information, Fig. S3).
Prediction and verification of HLA class I-binding
EBV latency antigen-derived peptides
Next, we assessed the impact of multiple HLA class I alleles
on the hierarchy of CD81 T cell responses against the spec-
trum of EBV latency proteins. For immunodominant
(a)
(b)
Fig. 3. Human leucocyte antigen (HLA) class I-restricted expansion
of latent membrane protein (LMP)2A-specific interferon (IFN)
g1CD81 T cells. (a) Percentages of total HLA class I-restricted
LMP2A-specific CD81 T cell responses generated in vitro from
healthy Epstein–Barr virus (EBV) seropositive HLA-A*02
heterozygotes (n 5 9). Only HLA-A*02-restricted responses were
significantly above zero. (b) The combined expansion of LMP2A-
specific IFN-g1CD81 T-cells is shown for all donors from the three
HLA-A*02 heterozygote combinations. Each bar depicts the
percentage of LMP2A-specific IFN-g1CD81 T cells expanded from
one of the six peptide pools. The peptide pools are described in
Supporting information, Table S2.
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proteins, we tested EBNA3A/3B/3C (very few EBNA2 and
EBNA-LP epitopes have been identified) [50]. Based on
our earlier findings, subdominant proteins were restricted
to LMP1/LMP2A and not EBNA1. Initially, we selected
‘defined’ epitopes shown previously to elicit CD81 effector
T cell immunity. For EBNA3A/3B/3C proteins, several such
epitopes presented by a variety of HLA class I molecules are
known. By contrast, for LMP1/LMP2A, there are relatively
few defined HLA class I epitopes, with the exception of
peptides presented by HLA-A*02 [12,51,52]. As HLA-
A*01, HLA-A*03 and HLA-B*37 have each been associated
with differential susceptibility to EBV1 lymphomas
[15–17,53], we aimed to increase the number of defined
EBV latency antigen-derived epitopes restricted by these
HLA class I molecules. To achieve this, we screened for
potential HLA class I binding peptides using the bioinfor-
matic algorithm ‘SYFPEITHI’ [29]. Thirty functionally
defined epitopes (Supporting information, Table S3) were
scored by the algorithm in order to define the parameters
by which predicted peptides were to be selected. Defined
epitopes had a ‘SYFPEITHI’ score ranging from 7 to 36
(mean: 234). To reduce the likelihood of predicted pep-
tides being unable to bind to the relevant HLA class I mole-
cule, we selected a cut-off value that excluded the bottom
20th centile of the defined epitopes (‘SYFPEITHI’ score:-
 21). A total of 31 predicted peptides were used with HLA
class I peptide binding scores 21 (range5 21–31; mean
score5 261).
Binding of predicted HLA-A*03-restricted peptides was
confirmed using the HLA class I stabilization assay on live
T2 cells, which lack the transporter associated with antigen
processing, transfected with HLA-A*03 (Fig. 4a) [30]. Using
this approach, we confirmed that all 10 predicted peptides
bound HLA-A*03. As no stable HLA-A*01-transfected T2
cell line was available, binding was confirmed for all pre-
dicted HLA-A*01-restricted peptides using in-vitro HLA-
A*0101-peptide refolding and thermal stability CD analysis.
The maximum mAU at 280 nm for each 1l HLA-A*0101
refold is shown in Fig. 4b. For all peptides, the purity of the
peak containing properly refolded HLA-A*0101-peptide
was confirmed by SDS gel electrophoresis. All the peptides,
with the exception of the negative control, generated detect-
able amounts of conformationally intact HLA-A*0101.
Melting temperatures (TM) ranged between 408C and 728C
(Fig. 4c), indicating that all the HLA-A*0101-peptide var-
iants were stable at or above body temperature. Values for
(a)
(b)
(c)
Fig. 4. Human leucocyte antigen (HLA) class I peptide binding
assays for algorithm-predicted peptides. (a) HLA-A*03 binding of
predicted peptides was confirmed using a T2 cell line transfected
with HLA-A*03. Peptides were added at concentrations of 10 lM or
100 lM, and HLA class I expression was measured by flow
cytometry analysis using an aHLA-A*03 antibody. Data are shown
as the mean fluorescence intensity above the negative control.
(b) HLA-A*01 binding of predicted peptides was confirmed by
in-vitro refolding. Maximum mAU values are shown. Positive control
peptides are in shown in bold type. The negative control peptide is
shown in italics. (c) Thermal stability with respect to melting
temperature (upper panel) and van’t Hoff ’s enthalpy of unfolding
(lower panel). Error bars represent standard error of the respective
parameter based on fitting each set of measured data. Positive
control peptides are shown in bold type.
3
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van’t Hoff ’s enthalpy of unfolding ranged from 2110 to
2700 KJ mol21, with more negative values indicating a
higher ratio of folded to misfolded peptide. Consistent with
the indications from the refolding data, the positive control
peptides and LMP2AESE were the most stable complexes
overall (i.e. highest overall TM range and most negative
van’t Hoff ’s enthalpy of unfolding values). Peptides
LMP2ALTE and LMP1LLA were also towards the high end of
the stability range. Although the other peptides tested dem-
onstrated a range of different stabilities, all the HLA-
A*0101-peptide variants generated a CD signal consistent
with the presence of properly refolded HLA class I. The pre-
dicted HLA-B*37-restricted peptides are identified in Sup-
porting information, Table S3 and Fig. 5, but HLA class I
binding was not tested directly, as neither the in-vitro HLA-
B*37-peptide refolding system nor a stable HLA-B*37-
transfected T2 cell line was available.
LMP1/LMP2A-specific CD81 T cell responses are
confined to HLA-A*02
The defined and predicted peptide epitopes listed in
Supporting information, Table S3 were used to investi-
gate the HLA class I hierarchy of ex-vivo effector CD81
T cell responses to immunodominant and subdominant
EBV latency proteins. Blood samples were obtained
for this purpose from 30 healthy participants (mean
age5 44 years; female/male ratio: 15 : 15). CD107 was
selected as the single functional readout, as it was the
only functional marker to reach significance in the pre-
vious ex-vivo assays reported above. As we were testing
for individual and not pooled (total) peptide responses,
CD107b was combined with CD107a to enhance
sensitivity.
Initially, we compared CD107ab1CD81 T cell responses
against 30 subdominant LMP1/LMP2A peptides (15 pre-
dicted and 15 defined, presented by nine different HLA
class I allotypes; Fig. 5a). The defined epitopes were pre-
sented by HLA-A*02, A*11, A*24, B*08, B*35 or B*60.
Each of these alleles is present at a carrier frequency
of> 10% in the Australian population. The predicted pep-
tides were presented by HLA-A*01, A*03 or B*37. The
rationale for focusing on these three HLA class I alleles has
already been outlined. Within the Australian population,
the total frequencies of HLA-A and HLA-B allotypes that
restrict these peptides (defined and predicted) are 75 and
33%, respectively.
We were unable to detect ex-vivo responses significantly
above zero for any of the individual peptides, regardless of
HLA class I restriction (Fig. 5a). However, by grouping the
individual peptide responses into the total response for
each HLA class I allele, we found that the HLA-A*02-
restricted responses were significantly greater than zero
(P5 0016). This was not observed for HLA-A*01, HLA-
A*03, HLA-B*37 or the group of defined peptides for
HLA-A*11, A*24, B*08, B*35 and B*60. These results indi-
cate that, despite their modesty in the ex-vivo setting,
HLA-A*02-restricted responses are dominant for LMP1/
LMP2A.
(a) (b)
Fig. 5. Hierarchy of ex-vivo human leucocyte antigen (HLA) class I-restricted CD81 T cell responses to known and predicted peptides derived
from latent membrane protein (LMP)1/LMP2A and EBNA3A/3B/3C. The ex-vivo CD107ab1CD81 T cell responses to individual peptides are
shown. Complete epitope sequences are listed together with the restricting allotypes; further details are shown in Supporting information, Table
S3. Error bars represent standard error of the mean. #Predicted HLA-B*37-restricted peptides with unconfirmed binding. (a) Subdominant
LMP1/LMP2A-derived epitope-specific responses. (b) Immunodominant EBNA3A/3B/3C-derived epitope-specific responses. The P-values
indicate significance of combined peptide responses above zero: **P< 001; *P< 005; P> 0055not significant.
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Next, we compared ex-vivo CD81 T cell responses to the
immunodominant EBV latency-III proteins EBNA3A/3B/
3C, which are not expressed in EBV1cHL. To keep the
analysis comparable with EBV latency-II antigens, we used
31 peptides (16 predicted and 15 defined, presented by
eight different allotypes; Fig. 5b). As with LMP1/LMP2A,
we included peptides presented by HLA-A*01, A*02, A*03
and B*37, including a defined EBNA3A-derived HLA-
A*03-restricted epitope and a defined EBNA3C-derived
HLA-B*37-restricted epitope. Other defined EBNA3A/3B/
3C-derived epitopes were presented by HLA-B*07, B*08,
B*35 or B*44, which account for 50% of HLA-B alleles in
Australian populations.
As shown in Fig. 5b, we were able to detect responses to
EBNA3A/3B/3C that were significantly greater than zero
for one of two HLA-A*02-restricted peptides (EBNA3ASVR)
and five of 11 HLA-B*07/B*08/B*35/B*44-restricted pep-
tides (EBNA3AFLR, QAK, YPL, EBNA3CEGG, KEH). None of
the other alleles generated responses significantly greater
than zero. The total responses to peptides presented by
HLA-A*02 and HLA-B*07/B*08/B*35/B*44 were both sig-
nificantly greater than zero (P5 00126 and P< 00001,
respectively). The magnitudes of the HLA-B*07/B*08/
B*35/B*44-restricted EBNA3A/3B/3C-specific responses
were significantly greater than the HLA-A*02-restricted
EBV latency-II responses (P5 00008).
In summary, we were able to detect ex-vivo responses to
EBNA3A/3B/3C-derived peptides restricted by several HLA
class I allotypes. By contrast, responses to EBV latency-II
peptides were detected only in the context of HLA-A*02.
Thus, the immunodominant EBV latency-III proteins gen-
erate strong CD81 T cell responses through a broad range
of HLA class I allotypes, whereas the subdominant proteins
expressed in EBV1cHL generate modest responses through
a single common allotype, namely HLA-A*02.
Discussion
In this study, we investigated the immunopathology under-
pinning the decreased frequency of HLA-A*02 carriers
observed in EBV1cHL. The results indicate that this is not
a surrogate association, but rather reflects the impact of
HLA class I on the established hierarchy of CD81 T cell
responses against EBV latency-II antigens. To reach these
conclusions, we used a series of distinct but complemen-
tary approaches.
Our initial investigation assessed relevant gene expression
in the diseased tissues of cHL patients. Intriguingly, we
observed a strong correlation between LMP2A and CD8 in
diagnostic EBV1cHL lymph nodes. Importantly, for a given
level of LMP2A, intratumoral CD8 expression was higher in
HLA-A*02-ve compared to HLA-A*021 EBV1cHL patients.
These data imply that CD81 T cell anti-tumoral immunity
is relatively ineffective in HLA-A*02– EBV1cHL. This is con-
sistent with a study that found intratumoral LMP2A-
specific CD81 T cells difficult to detect in EBV1cHL [40].
To test if the presence of HLA-A*02 impacts anti-tumoral
immunity in EBV1cHL, we assessed ex-vivo responses to
relevant EBV latency antigens in pretherapy cHL patients. In
order to obtain an unbiased and more comprehensive
assessment of CD81 T cell immunity with high sensitivity
and specificity, we used overlapping EBNA1/LMP1/LMP2A
peptide pools and measured both cytokine production
(IFN-g and TNF-a) and degranulation (CD107a) [35,36].
Even a modest cohort size was sufficient to observe signifi-
cantly reduced LMP1/LMP2A antigen-specific CD81 T cell
immunity in newly diagnosed HLA-A*02– versus HLA-
A*021 EBV1cHL patients. No differences between HLA-
A*021 and HLA-A*02– immune responses were observed in
either EBV–cHL patients or healthy participants. These find-
ings suggest that diminished immune-surveillance as a result
of HLA class I hierarchies may be pertinent only to the
pathogenesis of EBV1cHL. Although this approach enabled
an unbiased evaluation of relevant anti-tumoral immunity
in EBV1cHL, ex-vivo assays are less sensitive than in-vitro
expansion for the detection of low-frequency EBV-specific
CD81 T cells [43]. Furthermore, these results were con-
founded by the presence of additional HLA-A/B molecules
potentially masking single allele-based effects.
To overcome these limitations and specifically test the
impact of individual HLA class I alleles on relevant EBV-
specific CD81 T cell immunodominance hierarchies,
peptide-pulsed single HLA class I-restricted cell lines were
used to expand LMP2A-specific CD81 T cells in vitro from
EBV-seropositive healthy HLA-A*02 heterozygotes. In-vitro
expansion would permit more sensitive discrimination of
the impact of HLA class I status on CD81 T cell immuno-
dominance hierarchies than ex-vivo analysis. IFN-g-
specific CD81 T cells inhibit in-vitro transformation of
EBV-infected B cells [47,48]. The cytokine exerts its effects
via the canonical JAK–STAT pathway that is known to be
over-expressed in HRS cells [49], and therefore the IFN-g-
specific CD81 T cell response is likely to be important in
the pathogenesis of EBV1cHL. Thus IFN-g production was
chosen as a highly relevant in-vitro measure of effector
function. Strikingly, approximately 90% of all HLA class
I-restricted LMP2A-specific IFN-g-producing CD81 T cell
responses generated were elicited through HLA-A*02 com-
pared to the A*01, A*03 and B*08 allotypes. Previous work
using these cell lines assessed the response to endogenously
processed EBV latency-III antigens. In contrast, our novel
approach enabled us to narrow our assessment to the
EBV1cHL-relevant protein LMP2A [25]. From our ex-vivo
analysis (and consistent with previous work in healthy
EBV-seropositive individuals) [12], LMP2A-specific IFN-
g1 effector CD81 T cell responses were modest, but none
the less higher than for LMP1 or EBNA1. These data impli-
cate LMP2A as a critical target for effector CD81 T cells in
the immunopathogenesis of EBV1cHL. This is consistent
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with the correlation between LMP2A, but not LMP1 or
EBNA1, and intratumoral CD8 expression, with data show-
ing that LMP1 and EBNA1 encode for peptides that stimu-
late IL-10-secreting regulatory T cells [38,39], and with the
observation that EBNA1 predominantly (but not exclu-
sively) generates a CD41 effector T cell response [12].
To substantiate the emerging hypothesis, we tested the
influence of HLA class I on the hierarchy of CD81 T cell
responses across the spectrum of EBV latency antigens in
healthy seropositive donors. The immunodominant
(EBNA3A/3B/3C) and subdominant (LMP1/LMP2A) viral
antigens were compared. To enable a comprehensive evalu-
ation, in addition to functionally defined epitopes, we
adopted computational analysis to predict novel HLA class
I-restricted epitopes. Predicted epitopes were selected using
stringent criteria. The prerequisite for a predicted peptide
to be a potentially immunogenic CD81 T cell epitope is an
ability to bind to an HLA class I molecule (although the
magnitude of binding is not in itself an accurate forecast of
immunogenicity) [54]. Extensive assays were used to con-
firm HLA class I binding in all cases, with the exception of
HLA-B*37-restricted LMP1/LMP2A peptides for which
validated reagents were lacking. Equal numbers of defined
and predicted peptides with equivalent HLA class I cover-
age for the immunodominant and subdominant EBV
latency proteins were tested in a large number of healthy
EBV-seropositive donors. Strikingly, EBNA3A/3B/3C-spe-
cific CD81 T cell responses were stimulated by peptides
presented by numerous HLA class I allotypes. By contrast,
the relatively modest EBV latency-II-specific CD81 T cell
responses were confined largely to HLA-A*02.
These findings indicate that HLA class I impacts EBV
latency-II antigen-specific CD81 T cell response hierarchies
and provide a mechanistic basis for the immunopathogen-
esis of EBV1cHL. In EBV1 HRS cells, antigen presentation
is intact and restoration of relevant EBV-specific T cell
immunity can induce EBV1cHL regression [8–11]. Indeed,
HLA class I expression is more evident in EBV1cHL than
EBV–cHL [7,16]. The lack of selection pressure to down-
regulate HLA class I in virus-associated cHL indicates that
this strategy is not required to evade tumour-associated
CD81 T cell immunity. These results provide a mechanism
by which HRS cells can avoid CD81 T cell-mediated
immune attack despite intact antigen presentation.
The factors that determine CD81 T cell immunodomi-
nance have largely been investigated in animal models and
include antigen abundance, temporal antigen presentation,
CD81 T cell precursor frequency, the priming environment
and T cell receptor (TCR)/peptide-HLA class I binding
affinity [55]. Here, we demonstrate that HLA class I restric-
tions influence established EBV latency antigen-specific
CD81 T cell hierarchies. One explanation for this observa-
tion might be preferential handling of EBV latency-II anti-
gens by the HLA-A*02 processing pathway. Notably, for
human cytomegalovirus, strong viral epitope-specific
responses restricted by HLA-A*02 and HLA-A*01 have
been identified [56], suggesting that the influence of HLA
class I on CD81 T cell immunodominance may be virus-
dependent. Further studies are required to address the
issue.
A limitation of this study is that the findings do not dis-
criminate between reduced immune reactivity being due to
diminished antigen recognition of non-HLA-A*02 latency-
II antigens, or alternatively an anergic phenotype or a
reduced frequency of memory T cell precursors. After acute
EBV infection, a large CD81 T cell response is elicited
which contracts subsequently into a smaller memory pool
[57–59]. Interestingly, it is known that at least one HLA-
A*02-restricted lytic epitope reactivity present in the acute
phase consistently disappears once infection resolves [57].
Although this phenomenon has not been observed for
latent epitope reactivity, we cannot rule out definitively
that non-HLA-A*02 latency-II antigens induced a T cell
response in the acute phase, which was subsequently
extinguished in the memory phase. Alternatively, non-
HLA-A*02 latency-II antigen-specific CD81 T cells may be
relatively enriched in inhibitory receptors such as pro-
grammed cell death protein 1 (PD-1), relative to HLA-
A*02 latency-II antigen-specific CD81 T cells. Although
there are major histocompatibility complex (MHC) class I
multimers for HLA-A*02 latency-II antigen-specific CD81
T cells, the lack of defined epitopes means there are no
such reagents to directly visualize and phenotype non-
HLA-A*02 latency-II antigen-specific CD81 T cells.
Population-based studies have demonstrated a positive
association between infectious mononucleosis and cHL
[60]. However, this does not necessarily implicate EBV in
the aetiology of cHL. It may, instead, reflect a predisposi-
tion to a particular clinical response to primary EBV infec-
tion, perhaps as a consequence of a predating immune
impairment. In addition, transformation of EBV latency-
II-expressing benign B cells may represent an initiating
event in the pathogenesis of EBV1cHL. EBV-infected ger-
minal centre B cells have been shown to express the EBV
latency-II pattern [61,62], identical to that seen in the HRS
cells of EBV1cHL, which are known to have an atypical
germinal centre derivation [63]. In this situation, differen-
tial EBV latency-II-specific effector CD81 T cell immune
surveillance might contribute to the pathogenesis of
EBV1cHL by attenuating immune-mediated destruction of
premalignant B cells. Using functional assays that removed
the confounding influence of co-expressed HLA alleles, we
confirmed that HLA class I status indeed conferred differ-
ential levels of EBV latency-II-specific effector CD81 T cell
immunity in healthy seropositive participants. Here, those
peptide pools (4–6) that contained HLA-A*02 restricted
defined LMP2A epitopes contributed> 80% of the HLA-
A*02 CD81 T cell response, whereas the remaining pools
(1–3) provided< 20%. However, reduced ex-vivo HLA-
A*02– global (i.e. mediated through all co-expressed HLA-
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alleles) LMP1/LMP2A-specific effector CD81 T cell
responses were observed only in EBV1cHL patients. These
results suggest that EBV latency-II-specific effector CD81
T cell immune surveillance is particularly relevant to the
pathogenesis of EBV1cHL. Further investigations into
associations with disease outcome may be informative;
however, given the high response rate in cHL very large
numbers of uniformly treated patients would be required
to be sufficiently powered.
Collectively, our data provide new insights into the
immunopathogenesis of EBV1cHL and suggest that even
modest CD81 T cell responses directed against tumour-
associated viral proteins may reduce the incidence of
malignant disease. Further studies are required to deter-
mine if similar mechanisms are applicable to other malig-
nancies with EBV latency-II expression patterns, such as
extranodal natural killer (NK)/T cell lymphoma and undif-
ferentiated nasopharyngeal carcinoma [64,65].
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